Janux Therapeutics, Inc. (JANX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 07, 2025

$39.37

P/E Ratio

N/A

Market Cap

$2.28B

Description
Add to research

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerJANX
  • Price$39.37-3.22%

Trading Information

  • Market cap$2.28B
  • Float82.71%
  • Average Daily Volume (1m)991,718
  • Average Daily Volume (3m)1,177,480
  • EPS-$1.18

Company

  • Revenue$13.05M
  • Rev growth (1yr)-82.56%
  • Net income-$28.06M
  • Gross margin-16.17%
  • EBITDA margin-8,048.29%
  • EBITDA-$35.33M
  • EV$1.85B
  • EV/Revenue141.56
  • P/EN/A
  • P/S164.82
  • P/B3.14
  • Debt/Equity3.57
Documents
Add to research